Persion Pharmaceuticals LLC v. Alvogen Malta Operations Ltd., No. 18-2361 (Fed. Cir. Dec. 27, 2019)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Persion Pharmaceuticals LLC appeals from a decision of the U.S. District Court for the District of Delaware find- ing the asserted claims of U.S. Patent Nos. 9,265,760 and 9,339,499 invalid as obvious and lacking adequate written description. Because we find no reversible error in the dis- trict court’s obviousness determination , we affirm on that basis and do not reach the written description issue. B ACKGROUND I. The Asserted Patents Persion Pharmaceuticals LLC (“Persion”) 1 owns U.S. Patent Nos.